When to Use Gastric Protection with NSAIDs
Gastroprotective therapy should be prescribed for any patient taking NSAIDs who has at least one gastrointestinal risk factor, and is mandatory for all patients taking NSAIDs with concurrent low-dose aspirin. 1
Risk Stratification Framework
The decision to add gastroprotection depends on identifying specific GI and cardiovascular risk factors:
High GI Risk Factors (Require Gastroprotection):
- Age ≥65 years 1, 2
- Previous peptic ulcer disease (uncomplicated or complicated with bleeding/perforation) 2
- Concurrent antiplatelet therapy (aspirin, clopidogrel) 1
- Concurrent anticoagulation (warfarin) 2
- Concurrent corticosteroid use 2
- High-dose NSAID therapy 3
- Multiple NSAID use (including OTC NSAIDs combined with prescription) 1
The Clinical Reality
The evidence shows that 70% of at-risk NSAID users do not receive appropriate gastroprotection in actual practice 3, despite clear guidelines. The most commonly missed group is patients on high-dose NSAIDs (69.2% of at-risk patients) 3.
Specific Gastroprotection Strategies
For Low GI Risk + Low CV Risk:
- Non-selective NSAID + PPI, OR
- Celecoxib alone 4
For Low GI Risk + High CV Risk:
For High GI Risk + Low CV Risk:
- Celecoxib + PPI 4
For High GI Risk + High CV Risk:
For Any NSAID + Aspirin Combination:
- Always prescribe gastroprotection - this combination substantially increases ulcer complication risk 1
- PPI is the gastroprotective agent of choice 5
Critical Pitfalls to Avoid
H2-receptor antagonists at lower-than-recommended doses constitute 59% of inappropriate gastroprotection and are inadequate 3. PPIs are the gastroprotective drug of choice, not H2-blockers 5.
COX-2 inhibitors lose their GI safety advantage when combined with aspirin - this remains underappreciated by clinicians 1. These patients still need PPI co-therapy.
Helicobacter pylori eradication should be performed in patients with previous peptic ulcer or NSAID-naïve users before starting chronic NSAID therapy 5.
The Magnitude of Risk
Without gastroprotection, NSAIDs cause:
- Upper GI events in 1 of every 20 NSAID users (1 in 7 older adults) 1
- Annual incidence of serious GI events: 2.0-4.5% 1
- Risk of bleeding, perforation, or obstruction: 0.2-1.9% 1
- Approximately 107,000 hospitalizations and 16,500 deaths annually in the US 1
NSAIDs increase GI-related mortality 3-fold in elderly patients, even after adjusting for age and comorbidities 1.
Monitoring Requirements
Patients must have normal renal function at commencement with ongoing monitoring recommended 4, as NSAIDs carry significant nephrotoxicity risk 6.